Modern Retina Newsletter

To view this email as a web page, click here.

Recent study shows Alzheimer's disease biomarkers in the vitreous

Alzheimer's disease leads to severe cognitive dysfunction and eventual death; by 2050 it is expected to affect more than 115 million people worldwide. From time of diagnosis until death the average survival time is just under 5 years. Now, according to a recent study, biomarkers in the vitreous can indicate the likelihood of developing Alzheimer's.

Continue

The subthreshold laser's role in retinal vascular disease

A novel subthreshold laser provides seamless adjunctive therapy that can supplement or obviate the need for future injections in certain retinal conditions, explains Netan Choudhry, MD

OCTA may be harbinger of anti-VEGF efficacy

When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.

Find out

Don’t miss the Microdose of Reality2 Educational event at AAO!

Celebrate 3 years of ILUVIEN and join expert faculty as they discuss how they incorporate ILUVIEN into their practice.

To register for the event and to learn more, visit [www.iluvien.com/aao]

Risuteganib for the treatment of DME

Light induced visual-response: Objective, functional vision testing

Achromatopsia: Understanding the rare inherited retinal disease

Diabetic eye disease advances, but questions remain

Dinner program with expert presentations on Wet AMD and DME – Saturday, October 27, 2018 in Chicago, brought to you by Ophthalmology Times and Regeneron.

Save your seat now. »

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.